Soleno Therapeutics Stock (NASDAQ:SLNO)
Previous Close
$40.61
52W Range
$32.63 - $90.32
50D Avg
$41.48
200D Avg
$60.80
Market Cap
$2.10B
Avg Vol (3M)
$1.51M
Beta
-3.03
Div Yield
-
SLNO Company Profile
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release, a once-daily oral tablet for the treatment of Prader-Willi Syndrome, which is being evaluated in an ongoing Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.
SLNO Performance
Peer Comparison
| Ticker | Company |
|---|---|
| AAPG | ASCENTAGE PHARMA GROUP INTERNATIONAL |
| VKTX | Viking Therapeutics, Inc. |
| MIRM | Mirum Pharmaceuticals, Inc. |
| RARE | Ultragenyx Pharmaceutical Inc. |
| PRAX | Praxis Precision Medicines, Inc. |
| CELC | Celcuity Inc. |
| XENE | Xenon Pharmaceuticals Inc. |
| DYN | Dyne Therapeutics, Inc. |
| CNTA | Centessa Pharmaceuticals plc |
| APGE | Apogee Therapeutics, Inc. |